Oncology
Metastatic Prostate Cancer
Expert Perspectives® in PSMA+ mCRPC to Cover Key Topics in PSMA+ mCRPC Treatment
Overview
Expert Perspectives® delivers health care providers with insights from key thought leaders on the latest advancements and current practices in medicine, in a concise and timely format. Expert Perspectives® in PSMA+ mCRPC will feature community-selected experts and topics that we hope you will find of value in your clinical practice.
VIEW THE TOPICS:
<br>
Patient Care Perspectives
- Balancing Precision in Patient Selection with Equitable Access to Therapy
- Impacts from Exercise and Nutrition in Patients With Prostate Cancer
- Maturing Role of PSMA PET in Prognosis, Treatment Selection and Response Assessment
- Metastatic Prostate Cancer On the Rise: Epidemiology Explored
- Opening Up Unexplored Avenues to Treat Lethal Prostate Cancer
- Optimizing Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer
<br>
Clinical Topic Updates
- Improving Prostate Cancer Screening Strategies to Reduce the Pool of Metastatic Disease
- Integrating Recent mCRPC FDA Approvals Into Clinical Practice
- Metabolic Health and Cardiovascular Risk in Patients With Prostate Cancer
- On-Treatment Biomarkers During PSMA-targeted Radioligand Therapy
- PARPi Benefit in Patients with Metastatic Castration-Resistant Prostate Cancer
- Second Taxane for Progression After Triplet Therapy: Treatment Considerations
<br>
Expert Roundtables
- Barriers to Progress and Opportunities for Innovation in Prostate Cancer Care
- Expert Roundtable Podcast: Redefining Precision Cancer Care: From -Omics to AI-Driven Biomarkers
- Integrating AI Across the Prostate Cancer Disease Continuum: Progress and Pitfall
